Viking Therapeutics Soars on Positive NASH Trial Results
TL;DR
Viking Therapeutics' liver disease treatment for nonalcoholic steatohepatitis (NASH) led to a significant reduction in liver fat and other lipid abnormalities in patients over 12 weeks compared to a placebo. The market for NASH treatments is expected to reach $24.3 billion by 2028. Viking's stock initially yo-yoed but hit a record high after the promising test results were unveiled, with shares trading near a record high and remaining well above their 50-day and 200-day moving averages.
- Top 1% Biotech Yo-Yos, But Hits A Record, On NASH Enthusiasm Investor's Business Daily
- Chasing Madrigal, Viking sails higher after NASH therapy slays midphase test FierceBiotech
- Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) Yahoo Finance
- Viking Therapeutics Clears Mid-Stage NASH Trial BioSpace
- Bulls Blast Viking Therapeutics Stock on Trial Data Schaeffers Research
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Investor's Business Daily